AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35922667 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL11A enhancer-edited, autologous, hematopoietic stem and progenitor cells
Number of subjects: 2
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Data driven model of Achilles tendon health
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Five uncorrelated factors identified: biopsychosocial, lower extremity function, body size, load tolerance, tendon structure
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Measurement Information System
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-movement jump height
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain with hopping
Number of subjects: 99
Study 35922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon cross-sectional area
Number of subjects: 99
Study 35922777 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype and chrononutrition interventions
Number of subjects: 166
Study 35922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal food preoccupation and responsiveness
Number of subjects: 458
Study 35922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy ultra-processed food intake (% of energy intake)
Number of subjects: 458
Study 35922793 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 458
Study 35922819 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC drugs only
Number of subjects: 600
Study 35922819 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC drugs and praziquantel
Number of subjects: 600
Study 35922819 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC drugs and albendazole and praziquantel
Number of subjects: 600
Study 35922819 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 600
Study 35922819 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 600
Study 35922861 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanexor 10 mg, administered on days 1-5 each week of a 28-day cycle
Number of subjects: 20
Study 35922861 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanexor 20 mg, administered on days 1-5 each week of a 28-day cycle
Number of subjects: 20
Study 35922861 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanexor (both doses combined)
Number of subjects: 20
Study 35922861 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanexor (efficacy-evaluable patients)
Number of subjects: 20
Study 35922860 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 4994
Study 35922860 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 4994
Study 35922860 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy duration
Number of subjects: 4994
Study 35922860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial co-infection at admission
Number of subjects: 4994
Study 35922860 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-acquired infections (ICU-AI)
Number of subjects: 4994
Study 35922868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial sheet transplantation
Number of subjects: 6
Study 35923658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - high engagement group
Number of subjects: 277
Study 35923658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - moderate engagement group
Number of subjects: 277
Study 35923658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - discontinued group
Number of subjects: 277
Study 35923658 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who completed 3 months of the study with higher AS engagement
Number of subjects: 277
Study 35923787 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR-positive children
Number of subjects: 162
Study 35923787 — intervention group
Group type: COMPARATOR
Intervention: Age-matched PCR-negative controls
Number of subjects: 162
Study 35923824 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCOMPAGNE program (educational program for patient/natural caregiver dyads)
Number of subjects: 0
Study 35923824 — intervention group
Group type: COMPARATOR
Intervention: Conventional approaches (control group)
Number of subjects: 0
Study 35923824 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCOMPAGNE program
Number of subjects: 0
Study 35923923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab (H), pertuzumab (P), and paclitaxel for 16 weeks
Number of subjects: 23
Study 35923923 — intervention group
Group type: EXPERIMENTAL
Intervention: D8 biopsies
Number of subjects: 23
Study 35923926 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB) + tissue testing (TT) using Guardant360™ assay
Number of subjects: 0
Study 35923926 — intervention group
Group type: COMPARATOR
Intervention: Tissue testing (TT) alone
Number of subjects: 0
Study 35923928 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 77
Study 35924212 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing to a 14-min video led by a voice expert
Number of subjects: 60
Study 35924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 100
Study 35924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential drivers (PDs) identified using ECGI mapping
Number of subjects: 100
Study 35924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden of rotational PDs, rotational stability, and burden of PDs occurring at the pulmonary veins and posterior wall
Number of subjects: 100
Study 35924778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher suPAR levels
Number of subjects: 1960
Study 35924778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher D-dimer levels
Number of subjects: 1960
Study 35924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine CrAg testing
Number of subjects: 1333
Study 35924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerprick whole blood CrAg testing
Number of subjects: 1333
Study 35924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both POC CrAg tests
Number of subjects: 1333
Study 35925037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 3124
Study 35925040 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred, theory-based oral health education program
Number of subjects: 19
Study 35925555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 1200 mg/day for 2 weeks
Number of subjects: 47
Study 35925555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 1800 mg/day for 2 weeks
Number of subjects: 47
Study 35925555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole (various regimens)
Number of subjects: 47
Study 35925555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 35925583 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of rare CFH variants
Number of subjects: 23
Study 35925583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare variant P258L
Number of subjects: 23
Study 35925612 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Criteria of Good Disease Management of Diabetes established by the Swiss Society of Endocrinology and Diabetology (SSED)
Number of subjects: 727
Study 35925612 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the SSED criteria
Number of subjects: 727
Study 35925612 — intervention group
Group type: EXPERIMENTAL
Intervention: SSED criteria implementation
Number of subjects: 727
Study 35925686 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for acute VTE
Number of subjects: 98
Study 35925717 — intervention group
Group type: EXPERIMENTAL
Intervention: We-talk in caregivers of children with rare or undiagnosed diseases
Number of subjects: 0
Study 35925717 — intervention group
Group type: COMPARATOR
Intervention: We-talk in caregivers of typically developing children
Number of subjects: 0
Study 35925831 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanting new leads in patients with dislodged leads
Number of subjects: 20683
Study 35925831 — intervention group
Group type: COMPARATOR
Intervention: Lead dislodgement events
Number of subjects: 20683
Study 35925831 — intervention group
Group type: COMPARATOR
Intervention: Passive fixation type leads
Number of subjects: 20683
Study 35925831 — intervention group
Group type: COMPARATOR
Intervention: Female sex and higher body mass index
Number of subjects: 20683
Study 35925981 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation program
Number of subjects: 300
Study 35926075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D camera guidance (camera on)
Number of subjects: 3118
Study 35926075 — intervention group
Group type: COMPARATOR
Intervention: Laser-guided positioning (camera off)
Number of subjects: 3118
Study 35926201 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy
Number of subjects: 10572
Study 35926201 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy
Number of subjects: 10572
Study 35926204 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 200-500 micrograms/kg IV over 2 minutes, repeated every 5 minutes until appropriate analgesia was achieved
Number of subjects: 110
Study 35926204 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl 0.5-1 micrograms/kg IV over 2 minutes, repeated every 5 minutes until appropriate analgesia was achieved
Number of subjects: 110
Study 35926204 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine
Number of subjects: 110
Study 35926204 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl
Number of subjects: 110
Study 35926241 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA alteration level (level 1: no alterations)
Number of subjects: 223
Study 35926241 — intervention group
Group type: EXPERIMENTAL
Intervention: ctle-RECIST based on ctDNA alteration level
Number of subjects: 223
Study 35926241 — intervention group
Group type: EXPERIMENTAL
Intervention: dual-DCR group
Number of subjects: 223
Study 35926332 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone levels
Number of subjects: 996
Study 35926332 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight loss intervention
Number of subjects: 996
Study 35926332 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels
Number of subjects: 996
Study 35926375 — intervention group
Group type: EXPERIMENTAL
Intervention: GCA/PMR
Number of subjects: 674
Study 35926375 — intervention group
Group type: COMPARATOR
Intervention: RA
Number of subjects: 674
Study 35926895 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS
Number of subjects: 136
Study 35926895 — intervention group
Group type: EXPERIMENTAL
Intervention: GWI
Number of subjects: 136
Study 35926895 — intervention group
Group type: EXPERIMENTAL
Intervention: GCW
Number of subjects: 136
Study 35926895 — intervention group
Group type: EXPERIMENTAL
Intervention: GWI and GCW
Number of subjects: 136
Study 35926895 — intervention group
Group type: EXPERIMENTAL
Intervention: MWIs
Number of subjects: 136
Study 35926941 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 35926961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis
Number of subjects: 0
Study 35926961 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological prosthesis
Number of subjects: 0
Study 35926961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35926961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 60 years
Number of subjects: 0
Study 35926961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with less than 5 years of evolution
Number of subjects: 0
Study 35926993 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care for rotator cuff repair (RCR)
Number of subjects: 141
Study 35927040 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Smax ablation (V-Smax)
Number of subjects: 178
Study 35927040 — intervention group
Group type: COMPARATOR
Intervention: Empirical ablation (E-ABL)
Number of subjects: 178
Study 35927208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 108
Study 35927208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 35927231 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (UMSCs) infusion
Number of subjects: 17
Study 35927368 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length double-stranded DNA (flDNA)
Number of subjects: 162
Study 35927368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregenomic RNA (pgRNA)
Number of subjects: 162
Study 35927368 — intervention group
Group type: EXPERIMENTAL
Intervention: Spliced1 RNA (sp1RNA)
Number of subjects: 162
Study 35927368 — intervention group
Group type: EXPERIMENTAL
Intervention: Spliced-derived DNA (defDNA)
Number of subjects: 162
Study 35927485 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding (n=13)
Number of subjects: 243
Study 35927485 — intervention group
Group type: EXPERIMENTAL
Intervention: Any human milk feeding
Number of subjects: 243
Study 35927485 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (n=230)
Number of subjects: 243
Study 35927539 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger plethysmography
Number of subjects: 100
Study 35927539 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography
Number of subjects: 100
Study 35927684 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAPAGE program (combined diet/physical activity intervention)
Number of subjects: 450
Study 35927684 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 450
Study 35927684 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAPAGE program
Number of subjects: 450
Study 35927710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional T-VEC (up to 4 mL, first dose as seroconversion dose) and systemic nivolumab (240 mg flat dose) every 2 weeks for four courses of T-VEC and three doses of nivolumab
Number of subjects: 24
Study 35927710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional T-VEC and systemic nivolumab
Number of subjects: 24
Study 35927713 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria care interventions during the COVID-19 pandemic
Number of subjects: 0
Study 35927713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment and use of insecticide-treated nets
Number of subjects: 0
Study 35927713 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of genetic markers of resistance to artemisinin derivatives and sulfadoxine-pyrimethamine
Number of subjects: 0
Study 35927713 — intervention group
Group type: COMPARATOR
Intervention: Retrospective, interrupted-time series analysis
Number of subjects: 0
Study 35927795 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-room indirect calorimeters
Number of subjects: 16
Study 35928271 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary aromatic amino acid metabolites
Number of subjects: 0
Study 35928510 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program (Future Patient Program)
Number of subjects: 137
Study 35928510 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 137
Study 35928870 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPVax (therapeutic cancer vaccine composed of two peptides derived from telomerase) combined with atezolizumab (anti-PD-L1)
Number of subjects: 0
Study 35928870 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 0
Study 35928890 — intervention group
Group type: COMPARATOR
Intervention: Sarcopenic obesity (SO) in patients with neurodisabilities
Number of subjects: 0
Study 35928890 — intervention group
Group type: COMPARATOR
Intervention: BMI and SMI scores in patients with neurodisabilities
Number of subjects: 0
Study 35928938 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Algorithm for Severe Atheromatosis Prediction (PASAP-ILERVAS)
Number of subjects: 0
Study 35928993 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of Processing (SoP) training plus alpha transcranial alternating current stimulation (α-tACS)
Number of subjects: 327
Study 35928993 — intervention group
Group type: COMPARATOR
Intervention: Speed of Processing (SoP) training alone
Number of subjects: 327
Study 35928993 — intervention group
Group type: COMPARATOR
Intervention: Active alpha transcranial alternating current stimulation (α-tACS) alone
Number of subjects: 327
Study 35928993 — intervention group
Group type: COMPARATOR
Intervention: Sham alpha transcranial alternating current stimulation (α-tACS)
Number of subjects: 327
Study 35928993 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of Processing (SoP) training plus α-tACS
Number of subjects: 327
Study 35929414 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Number of subjects: 0
Study 35929455 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin receptor substrate-1 rs956115 genotype
Number of subjects: 0
Study 35929455 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 rs4244285 genotype
Number of subjects: 0
Study 35929455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35929787 — intervention group
Group type: EXPERIMENTAL
Intervention: LMCAD present
Number of subjects: 2510
Study 35929787 — intervention group
Group type: COMPARATOR
Intervention: LMCAD absent
Number of subjects: 2510
Study 35929787 — intervention group
Group type: EXPERIMENTAL
Intervention: LMCAD present (after propensity score matching)
Number of subjects: 2510
Study 35929787 — intervention group
Group type: COMPARATOR
Intervention: LMCAD absent (after propensity score matching)
Number of subjects: 2510
Study 35929986 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5305 at doses ≥0.1 mg/kg once daily
Number of subjects: 0
Study 35929986 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 100 mg/kg once daily
Number of subjects: 0
Study 35929986 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5305
Number of subjects: 0
Study 35930017 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced computed tomography (CE-CT)
Number of subjects: 100
Study 35930017 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 100
Study 35930017 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gallium-DOTATOC positron emission tomography (68 Ga-DOTATOC PET)
Number of subjects: 100
Study 35930017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal metastases identification at ≥1 imaging technique
Number of subjects: 100
Study 35930078 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopic hematoma evacuation (MEHE)
Number of subjects: 0
Study 35930301 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 574
Study 35930331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting Healthy Plate (IFHP)
Number of subjects: 177
Study 35930331 — intervention group
Group type: COMPARATOR
Intervention: Healthy Plate (HP)
Number of subjects: 177
Study 35930336 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive mobile sensing using a mobile app for tracking activity, sociability, and sleep in patients with SMI over 9 months.
Number of subjects: 0
Study 35930336 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly assessments during the mobile sensing phase for 9 months.
Number of subjects: 0
Study 35930336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician interviews before and after the mobile sensing phase.
Number of subjects: 0
Study 35930351 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC plus biweekly grocery delivery
Number of subjects: 855
Study 35930351 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC plus biweekly grocery and unsweetened beverage delivery
Number of subjects: 855
Study 35930351 — intervention group
Group type: COMPARATOR
Intervention: Usual care from WIC (control)
Number of subjects: 855
Study 35930351 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 855
Study 35930353 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2498
Study 35930441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) with US-responsive carriers
Number of subjects: 0
Study 35930750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 36
Study 35930750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib retreatment
Number of subjects: 36
Study 35930972 — intervention group
Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 0
Study 35930972 — intervention group
Group type: COMPARATOR
Intervention: pemetrexed + platinum (KEYNOTE-189)
Number of subjects: 0
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Graft Function (DGF)
Number of subjects: 274
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive Nephropathy
Number of subjects: 274
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Ischemia Time (CIT)
Number of subjects: 274
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: DGF in body artery stenosis subgroup
Number of subjects: 274
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in body artery stenosis subgroup
Number of subjects: 274
Study 35931001 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model for TRAS risk prediction
Number of subjects: 274
Study 35931041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (0.5 mg/kg over 40 minutes)
Number of subjects: 38
Study 35931285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy for divalent metals (lead and cadmium)
Number of subjects: 0
Study 35931285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy (TACT2 trial)
Number of subjects: 0
Study 35931285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 0